Company: MDCXW
Filing Date: 2025-09-29
Form Type: S-1
Source: 0001062993-25-015839
Chunk: 154

Company: Medicus Pharma Ltd.
Filing Date: 2025-09-29
Form: S-1
Chunk 154
---
 as targeted radiotherapeutics, an exciting area of oncology drug development. Most recently, Mr. Mahaffy served as the Chairman of the Board of Antev from March 2024 until August 2025. Previously, Mr. Mahaffy was the President and CEO of Clovis Oncology, Inc. ("Clovis") (Nasdaq: CLVS), a company he co-founded in 2009. Under his leadership Clovis developed, gained approvals for and marketed Rubraca, a drug for ovarian and prostate cancer in the US and Europe, and commenced early-stage clinical development of a targeted radionuclide therapy.

Prior to Clovis, Mr. Mahaffy served as the President and CEO of Pharmion Corporation, a global drug development and commercialization company focused on hematological and solid tumor cancers, from 2000 to 2008 when it was acquired by Celgene (now Bristol Myers Squibb) for $2.9 billion. Its primary drug, Vidaza, remains today the standard of care for the treatment of myelodysplastic syndrome and acute myeloid leukemia.

Mr. Mahaffy's first role as CEO was at Nexstar Pharmaceuticals, focused on the discovery, development, manufacture and commercialization of products to treat serious and life-threatening illnesses including cancer. which he led from 1992 to 1998, prior to its 1999 acquisition by Gilead Sciences for $550 million. Nexstar's primary drug, Ambisome, remains the standard of care today for the treatment of certain life-threatening fungal infections. Mr. Mahaffy began his career at Warburg Pincus, where he served as a venture capitalist from 1986 to 1992.

Mr. Mahaffy holds a Master's degree in International Affairs from Columbia University, which he completed in 1986, a year after obtaining his Bachelor's degree in International Affairs from Lewis and Clark College. Pat is also a long serving member of the Board of Trustees for Lewis & Clark College.

Carolyn Bonner, President and Acting Chief Financial Officer

Carolyn Bonner has served as our President since September 2023. On September 12, 2025, in connection with Mr. Quinlan’s medical leave of absence, Ms. Bonner was appointed as acting Chief Financial Officer of the Company in addition to remaining the Company’s President.

Ms. Bonner until recently was the President & CEO of Parkway Clinical Laboratories (2019 to 2023), a College